Clinical Trials Logo

Gastrointestinal Carcinoid Tumor clinical trials

View clinical trials related to Gastrointestinal Carcinoid Tumor.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT00227773 Withdrawn - Clinical trials for Gastrointestinal Carcinoid Tumor

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Start date: n/a
Phase: Phase 2
Study type: Interventional

RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor. Octreotide may help control symptoms, such as diarrhea, caused by the tumor. Giving vatalanib together with octreotide may be an effective treatment for neuroendocrine tumors. PURPOSE: This phase II trial is studying how well giving vatalanib together with octreotide works in treating patients with progressive neuroendocrine tumors.